Market Place
Sourcing Support
Communication at the request of the FSMA on the transactions with Qliniq
14 Mar 2024 //
GLOBENEWSWIRE
Hyloris Reports Full Year Results for 2023 & Provides Business Outlook
14 Mar 2024 //
GLOBENEWSWIRE
Hyloris to Report 2023 Full-Year Results on 14 March 2024
08 Mar 2024 //
GLOBENEWSWIRE
Hyloris Enrolls First Patient in Phase 3 Trial for its Proprietary Mouth Rinse
14 Feb 2024 //
GLOBENEWSWIRE
Hyloris and Purna Announce Positive Results from Phase 2 Trial in Acute VVC
30 Jan 2024 //
GLOBENEWSWIRE
Hyloris Broadens Pipeline with new Product Candidate for VLS
18 Jan 2024 //
GLOBENEWSWIRE
Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of AML
16 Jan 2024 //
GLOBENEWSWIRE
Hyloris Announces Positive Clinical Study Results for Valacyclovir
26 Dec 2023 //
GLOBENEWSWIRE
Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome
21 Dec 2023 //
GLOBENEWSWIRE
Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in Canada
24 Oct 2023 //
GLOBENEWSWIRE
Hyloris Pharma wins US FDA approval for pain treatment
19 Oct 2023 //
GLOBENEWSWIRE
Hyloris announces U.S. FDA Approval of Maxigesic® IV
18 Oct 2023 //
GLOBENEWSWIRE
Hyloris Reports 2023 Half-Year Results and provides Business Outlook
06 Sep 2023 //
GLOBENEWSWIRE
Hyloris enrols first patient in four-arm clinical trial
22 Jun 2023 //
PHARMAFILE
Hyloris announces enrolment of first patient in a 4-arm trial of Alenura(TM)
21 Jun 2023 //
GLOBENEWSWIRE
Hyloris shareholders approve all resolutions at the Annual General Meeting
13 Jun 2023 //
GLOBENEWSWIRE
Hyloris has been granted EUR 1M in non-dilutive funding from the Walloon Region
08 Jun 2023 //
GLOBENEWSWIRE
Hyloris announces potential registration date for Maxigesic® IV in the US
02 May 2023 //
BIOSPACE
Hyloris announces potential registration date for Maxigesic® IV in the US
02 May 2023 //
GLOBENEWSWIRE
Hyloris releases Annual Report 2022, including ESG objectives
28 Apr 2023 //
GLOBENEWSWIRE
Hyloris announces subof Maxigesic IV packaging data requested by the US FDA
18 Apr 2023 //
GLOBENEWSWIRE
Hyloris reports full year results for 2022 & provides business outlook
15 Mar 2023 //
GLOBENEWSWIRE
Hyloris Announces Commercial Partnership for Maxigesic IV in European Countries
24 Jan 2023 //
GLOBENEWSWIRE
Hyloris expands Pipeline with a Candidate for a Mineral Deficiency in the Blood
20 Jan 2023 //
GLOBENEWSWIRE
Hyloris Broadens Pipeline with a Nasal Product Candidate for Idiopathic Rhinitis
22 Nov 2022 //
GLOBENEWSWIRE
Hyloris Announces Move to LégiaPark Complex Aligned with its Sustainable Growth
12 Oct 2022 //
GLOBENEWSWIRE
Hyloris Faces Trade-Secret Claims Over New Heart Arrhythmia Drug
01 Sep 2022 //
BLOOMBERG
Hyloris Reports Positive Phase 1 Data for HY-004
20 Jul 2022 //
GLOBENEWSWIRE
Hyloris Provides Addn. Information on FDA Review of NDA Appln. for Maxigesic IV
01 Jul 2022 //
GLOBENEWSWIRE
Hyloris Raises EUR 15M in an Equity Offering by Means of Private Placement
01 Apr 2022 //
GLOBENEWSWIRE
Hyloris Launches Equity Offering by Means of Private Placement
31 Mar 2022 //
GLOBENEWSWIRE
Hyloris Launches Equity Offering by Means of Private Placement
31 Mar 2022 //
GLOBENEWSWIRE
Correcting -- Hyloris reports results for the FY 2021
16 Mar 2022 //
GLOBENEWSWIRE
Kither Biotech Raises ¬18.5 M Series B; Appoints Dr. Vincent Metzler as CEO
15 Mar 2022 //
GLOBENEWSWIRE
Hyloris Enters into Strategic Partnership Vaneltix for Treatment of Acute Pain
17 Dec 2021 //
GLOBENEWSWIRE
Hyloris Announces Earlier than Expected PDUFA Date for Maxigesic® IV
13 Nov 2021 //
GLOBENEWSWIRE
Hyloris Broadens Pipeline with Novel Patented Combination Product Candidate
10 Nov 2021 //
GLOBENEWSWIRE
Hyloris Announces FDA Acceptance of New Drug Application for Maxigesic® IV
01 Nov 2021 //
GLOBENEWSWIRE
Hyloris Announces Approval of Maxigesic® IV in the UK and Ireland
19 Oct 2021 //
GLOBENEWSWIRE
Hyloris enters pact with Rhoshan for intravenous acetylsalicylic acid
14 Oct 2021 //
PHARMABIZ
Hyloris Acquires Breakthrough, Patented Technology to Develop Aspirin IV
13 Oct 2021 //
GLOBENEWSWIRE
Hyloris Expands Cardiovascular Pipeline with Breakthrough Extended-Release
08 Oct 2021 //
GLOBENEWSWIRE
Hyloris Announces Launch of Maxigesic® IV, in Key European Markets
08 Jul 2021 //
GLOBENEWSWIRE
Hyloris Successfully Renegotiates License Agreements with the Alter Pharma Group
24 Jun 2021 //
GLOBENEWSWIRE
Hyloris Announces Extension of Footprint of Maxigesic® IV into South America
06 May 2021 //
GLOBENEWSWIRE
Hyloris Announces Major Commercial Partnership in the U.S. for Maxigesic® IV
28 Apr 2021 //
GLOBENEWSWIRE
Hyloris and Purna Female Healthcare announce partnership to develop
05 Feb 2021 //
GLOBESNEWSWIRE
Hyloris announces approval of Maxigesic® IV in eight European countries
07 Sep 2020 //
GLOBENEWSWIRE
Hyloris Pharmaceuticals Raises approximately EUR 61.81 million
26 Jun 2020 //
GLOBENEWSWIRE
